Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT)

Cardiovascular Research

Volumn 52, Issue 2, 2001, Pages 290-298

  Malik, Jan ^a   Melenovsky, Vojtech ^a   Wichterle, Dan ^a   Haas, Tomas ^a   Simek, Jan ^a   Ceska, Richard ^a   Hradec, Jaromir ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Atherosclerosis; Cholesterol; Endothelial function; Regional blood flow; Statins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ABDOMINAL PAIN; ADULT; ARTERY DILATATION; ARTICLE; BIOCHEMISTRY; BLOOD FLOW; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPPLER ECHOGRAPHY; DRUG EFFECT; HUMAN; HYPEREMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULINEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; ARM; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PROCETOFEN; PYRROLES; REGIONAL BLOOD FLOW; REGRESSION ANALYSIS; TRIGLYCERIDES; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 0034782457     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00382-0     Document Type: Article

References (38)

1. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications
2. Assessment and treatment of endothelial dysfunction in humans
3. A noninvasive method of reactive hyperemia is useful in assessing endothelial function instead of intra-arterial vasoactive agent infusion method in humans
4. A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans
5. Endothelium-derived relaxing factor (EDRF) produced and released from artery and vein is nitric oxide
6. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC study)
7. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion
8. Lipids and the endothelium
9. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
10. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia
11. Influence of low density lipoprotein (LDL) subfraction and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes
12. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation. Reversal after lipid-lowering therapy by atorvastatin
13. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity
14. Effect of insulin resistance on the endothelial vasomotor function of the coronary artery of nondiabetic patients
15. Novel risk factors for atherosclerosis
16. Associations of C-reactive protein with measures of obesity, insulin resistance and subclinical atherosclerosis in healthy, middle-aged women
17. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease
18. Relation of inflammation to vascular function in patients with coronary heart disease
19. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidemia (FACT study). Fluvastatin alone and in combination treatment
20. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia
21. Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries
22. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
23. NO activity in familial combined hyperlipidemia: Potential role of cholesterol remnants
24. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
25. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection
26. Relation between endothelial dysfunction and laboratory parameters in patients with combined hyperlipidemia
27. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease
28. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
29. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study
30. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes
31. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability
32. The effects of atorvastatin and fenofibrate on the levels of malonyldialdehyde, homocysteine and the size of LDL particles in combined hyperlipidaemia
33. Medical significance of peroxisome proliferator-activated receptors
34. Does a glass of red wine improve endothelial function?
35. Methodological aspects of the evaluation of endothelium-dependent vasodilatation in the human forearm
36. What's wrong with Bonferroni adjustments